Passage Bio Inc logo


Passage Bio Inc


Earnings Summary

Net Profits


Net Profits:

Passage Bio Inc’s net profit jumped 18.36% since last year same period to $-39.54Mn in the Q2 2022. On a quarterly growth basis, Passage Bio Inc has generated 7.64% jump in its net profits since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Passage Bio Inc post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Passage Bio Inc’s earning per share (EPS) estimates for the current quarter stand at -0.83 - a 6.74% jump from last quarter’s estimates.

EPS Estimate Current Year:

Passage Bio Inc’s earning per share (EPS) estimates for the current year stand at -0.83.

Key Ratios

Key ratios of the Passage Bio Inc post its Q2 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Passage Bio Inc’s return on assets (ROA) stands at -0.29.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Passage Bio Inc’s return on equity (ROE) stands at -0.55.

Dividend Per Share (DPS):

Passage Bio Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Passage Bio, has the mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities it serves. Based in Philadelphia, PA, the company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania's Gene Therapy Program to conduct its discovery and IND-enabling preclinical work. This provides the team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that Passage Bio then pairs with its deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance its robust pipeline of optimized gene therapies into clinical testing. As the company works with speed and tenacity, Passage Bio is always mindful of patients who may be able to benefit from its therapies.

Passage Bio Inc
Health Technology